11170 RESULTS
COMMENT I want to bring to the attention of Alzforum readers my view that continuing support for the amyloid theory, which currently dominates AD research fields, is unnecessary and should be stopped. I believe this issue should be taken into consideration by sci
COMMENT This paper by the group of Michael Calhoun confirms, in vivo, a role for microglia in amyloid plaque maintenance. The authors succeeded in monitoring live changes in plaque size, and correlate them to changes in number and appearance of “on site” microgli
COMMENT This work described an interesting concept for targeting β-secretase to endosomes. The results show some promise. However, the improvement in the inhibition of Aβ production by sterol-modified inhibitors over the unmodified inhibitor was accomplished with
COMMENT The results of the LEADe study provide clear evidence that atorvastatin does not delay the progression of Alzheimer disease. This result contrasts with a previous, preliminary study on atorvastatin by Sparks and colleagues, and it is disappointing [1]. Ho
COMMENT Grönwall et al. (2007) recently applied phage-display techniques to identify affibody ligands that efficiently capture Aβ peptides from human plasma and serum. In the present paper by Hoyer et al., one of these phage-selected affibodies, Zab3, is shown to
COMMENT I believe the answer(s) to Alzheimer disease will be found by comparing early onset patients (in their forties, for example) to controls of the same age. We should find more striking differences than when we compare elderly AD patients with elderly contro
COMMENT The favorable effects of increased activity on quality of life in old age are well established, but this basic study, along with another recent paper (Santana-Sosa et al., 2008), adds to the evidence that AD patients also might benefit from increased acti
COMMENT This is the first paper to show (11)C-PiB binding in PET in hereditary cerebral amyloid angiopathy and APP locus duplication. The paper reports increased uptake of (11)C-PiB in the striatum and the posterior cingulate in two cases with APP duplication, wh
COMMENT In agreement with Dr. Vassar’s comments, the two inhibitors used in Dr. Hook’s study, CA074-Me and
COMMENT In a separate discussion, Dr. Vassar cites McConlogue et al. (2008), which shows that knocking out BACE1 in mice expressing human APP containing the wild-type β-secretase site (PDAPP) significantly reduces Aβ and amyloid plaques in support of his conclusi
COMMENT The experiments described by Head et al. may not elucidate the role played by senile plaques in AD dementia, but they do bolster the idea that amyloid disruption therapy is likely to be most efficacious when administered early in the course of the disease
COMMENT Therapeutic vaccination trials in Tg animals and humans have revealed that senile plaques, a cardinal pathologic feature of AD, are dynamic structures subject to dissolution by Aβ immunotherapy. Although Aβ deposits are a logical AD therapeutic focus, it
COMMENT This is a fascinating paper from the group of Mathias Jucker and Michael Calhoun studying in vivo interaction of amyloid plaques and their most intriguing and prominent cellular component—the microglia. Employing two-photon imaging of GFP-labeled microgli
COMMENT This is an excellent review for those interested in the role of obesity, insulin resistance, and diabetes in AD. This is an important research area as the population ages and obesity and diabetes are on the rise. The explanation of terms such as glucose i
COMMENT The paper by Bolmont and colleagues (2008) represents an elegant set of experiments designed to track microglia in a doubly-transgenic mouse model of AD. The authors crossed an Iba1-GFP transgenic (thereby labeling microglia green) with a co-injected APP/
